In conclusion, our results identify CDK6 as a master regulator in treatment-resistant relapsed multiple myeloma and provide a strong rationale for further investigating CDK6 inhibition together with IMiDs in multiple myeloma. This evidence concerns the gene CDK6 and plasma cell myeloma.